Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money

71% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.

5 Top Stories

Meta Smashes Record; Hyundai IPO?; Delivery Hero Woes

Every day, we handpick the 5 Top Stories stock market investors need to know. In 5 minutes, you’ll learn the stocks, CEOs, and money managers moving markets.

Meta Smashes Single-Session Record

Following its barnstorming earnings report on Thursday, Facebook-owner Meta [META] closed Friday 20% up, at an all-time high of $474.99 per share, boosting its market cap by $197bn. This represented the biggest-ever single-session spike, a record previously held by Apple [AAPL] and Amazon [AMZN], who both gained $190bn in 2022. The social media giant slashed 22% of roles last year, and announced plans for a $50bn stock buyback last week.

Hyundai: Ready to Ride the Indian IPO Wave?

The South Korean automaker [005380:KS] is hoping to raise $3bn by listing its Indian unit, Reuters reported. This would constitute India’s biggest IPO to date and value the unit at up to $30bn, although it would still be smaller than rivals including Tata Motors [TATAMOTORS:NS], at $41.4bn. Hyundai shares jumped 5% on the news, to a near-three-year high.

Delivery Hero Drop-off Continues

Extending last week’s losses, the Delivery Hero [DHER:DE] share price dipped as much as 8% on Monday morning. This follows the early release of preliminary financial results, which show the firm increased sales last year and is expecting to increase profitability in 2024. The decision to release the unaudited numbers ahead of schedule was prompted by a selloff in response to the firm’s asset sales strategy.

Leqembi Reaches China

Japanese pharma Eisai [4523:T] is to launch its Alzheimer’s drug Leqembi in China this year. It will initially be given to 1,500 patients, but the company anticipates significant growth as diagnostic methods change: more convenient blood tests could help Eisai reach more of the estimated 17 million people with early stages of the illness, a company spokesman said.

From Worse to Worse for Atos

Beleaguered French IT firm Atos [ATO:PA] saw its share price plunge as much as 30% to its lowest-ever level on Monday, after it dropped plans to sell €720m in equity rights, and announced it is bringing in a mediator to negotiate with lenders. The firm has had five CEOs in two-and-a-half years, and has lost billions of euros in market value since the end of 2020. It is also facing a number of debt maturities next year.    

Disclaimer Past performance is not a reliable indicator of future results.

CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.

The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.

CMC Markets does not endorse or offer opinion on the trading strategies used by the author. Their trading strategies do not guarantee any return and CMC Markets shall not be held responsible for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein.

*Tax treatment depends on individual circumstances and can change or may differ in a jurisdiction other than the UK.

Continue reading for FREE

Latest articles